Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Significant Decline in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant drop in short interest in September. As of September 15th, there was short interest totalling 10,400 shares, a drop of 5.5% from the August 31st total of 11,000 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 8,300 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent filing with the SEC. 34.19% of the stock is currently owned by institutional investors and hedge funds.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $2.88 on Monday. Aprea Therapeutics has a 52 week low of $2.25 and a 52 week high of $8.85. The company’s 50 day moving average price is $3.43 and its two-hundred day moving average price is $4.50. The company has a market capitalization of $15.64 million, a P/E ratio of -0.83 and a beta of 1.04.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. Analysts forecast that Aprea Therapeutics will post -2.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on APRE. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a research report on Monday, August 12th. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.